In 2004, Gunn added a regular segment on biotechnology, BioTech Nation. It has emerged as the only regular weekly mainstream programming on biotech on the national and international scene, and features interviews with biotech leaders. In its regular feature: “BioIssue of the Week”, Gunn discusses the breaking news of the day with award-winning science journalist, David Ewing Duncan.
In the U.S., Tech Nation can be heard four times each weekend on the National Public Radio website’s 24-hour Program Stream (npr.org). It airs on nearly 200 public radio stations, with multiple airtimes on the NPR Channels on XM-Sirius Satellite Radio. Globally, Tech Nation is aired three times weekly on the NPR Channels of Sirius Internet Radio and airs 25 weekly to 177 countries via Armed Forces Radio International. Tech Nation podcasts remain permanently archived on the Internet, enabling anyone, anywhere to listen to these materials on demand.
-
This week on BioTech Nation, what is AI-Powered Biology? Dr. Shana Kelley, President of Bioengineering and Head of Biohub, Chicago for the Chan-Zuckerberg Initiative, discusses how AI can be used to accelerate research, interpret data, and transform how new discoveries are made.
-
This week on Biotech Nation, Heather Turner of LB Pharmaceuticals joins to discuss a drug that’s new to the US, but not-so-new to Europe, where it’s already been in use for a couple of years. Intended for managing neuropsychiatric conditions like Schizophrenia, the drug is taken by several million people, but the approval process in the US has had to start back at square one. We look at why that is, and how LB is working on it.
-
When you think of FUJIFILM, you might be picturing rolls of camera film...but it turns out that's not all they've been working on. FUJIFILM Biotechnologies Chairman Toshi Iida joins to share more about how they're innovating in the world of biotech.
-
What if chemotherapy could be delivered in a focused way, directly to a tumor, and only where it's needed? Intensity Therapeutics Founder, President, & CEO Lew Bender shares how they're working to change how chemotherapy is delivered to solid tumors, personalized for each patient, with the hopes of reducing the toll it takes on the body.
-
This week on BioTech Nation, Jeff Liter of Luminary Therapeutics shares how his team is taking a new approach to advanced cell therapy, in the hopes of making it more accessible and affordable. Rather than formulating a custom treatment using a patient's own cells, they use healthy donor cells that are ready to go. This approach could help more people get treated for cancer and autoimmune diseases like lupus, with just a single dose.
-
On this episode of Biotech Nation...the story of how the United States' pharmaceutical industry came to be, and the people behind it all. Barry Werth joins Moira to discuss his new book, “The Age of Cures: How American Scientists Saved Your Life", about a handful of individuals who revolutionized research and helped build the drug development ecosystem we have today.
-
On this episode of BioTech Nation...Dr. James Mackay joins to talk about the progress Crystalys Therapeutics is making in the treatment of gout - a disease that affects more than 13 million people in the United States alone. Dr. Mackay debunks some common misconceptions surrounding the disease, and explains what Crystalys is doing to change the way doctors treat gout going forward.
-
You've probably heard of Peptides...but what exactly are they? And how do we know which ones are effective, and safe? Dr. Karsten Eastman, Co-Founder and CEO of Sethera Therapeutics, joins to answer all our questions about Peptides, and to tell us about Sethera's latest efforts to enhance peptides to make new medicines. Their plan: to develop a drug using enhanced peptides for Triple-Negative Breast Cancer... and they've already received funding.
-
This week on BioTech Nation, Sameer Sabir, CEO of Brixton Biosciences, shares how their breakthrough injectable cold therapy, Neural Ice, could offer lasting relief for osteoarthritis pain. With a drug-free, nerve-targeting approach currently in clinical trials, this innovation may change how we treat joint pain without pills or repeated steroid injections.
-
Imagine a world where the toughest wounds heal twice as fast, and patients get their lives back sooner than anyone thought possible. Dr. Ned Swanson, the President and Chief Medical Officer of Polarity Bio, tells us about their approach to healing serious, hard-to-treat skin wounds. In early trials, it's twice as effective as the current treatment for diabetic foot ulcers.